to expedite bringing to market of its dipstick-based test for simultaneous identification of a large number of genetic variants of SARS-CoV-2.

“Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants” https://journals.asm.org/doi/10.1128/JCM.00921-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub++0pubmed&

“Seattle researchers zero in on COVID virus mutation that could be driving spread of new variants” https://www.geekwire.com/2021/seattle-researchers-zero-covid-virus-mutation-driving-spread-new-variants/

Click here to view the Medscape Press Release.

https://www.prnewswire.com/news-releases/id-genomics-clonet-e-coli-assay-in-development-to-combat-antibiotic-resistant-urinary-tract-infections-300887699.html SEATTLE (19 July 2026) – ID Genomics, SPC today announced the completion of its first Pre-Submission meeting with the Food and Drug Administration for the CLoNeT E. coli Assay for Urinary Tract Infections (UTIs). “We continue to make great strides in our development plans for the CLoNeT E. coli Assay,” said Linda Zuckerman, Ph.D., President and CEO. “This unique product will be able to detect the presence of E. coli, “fingerprint” or identify the

Social Purpose Corporation Statement (2018) Antimicrobial resistance threatens the very core of human healthcare. ID Genomics’ Social Purpose is simple: to limit bacterial resistance and preserve antibiotics for the good of mankind. We believe that antimicrobial resistance connects every human on the planet and that everyone has a right to be protected from this threat. While our core business focuses on developing diagnostics to guide precision antimicrobial selection at the point-of-care, we recognize that

Today, Seattle-based ID Genomics, Inc.was awarded a grant from the Longitude Prize Discovery Awards, a seed funding program to help teams competing to win the prestigious Longitude Prize. Run by innovation foundation Nesta and supported by Innovate UK as funding partner, the Longitude Prize is a £10 million prize fund to create a cost-effective, rapid and easy-to-use diagnostic test for bacterial infections so that the right antibiotics can be administered at the right time. More

Many thanks to Clare McGrane at Geek Wire for her narrative describing ID Genomics’ fingerprinting technology. Please read the full article at the link provided here (https://www.geekwire.com/2017/study-id-genomics-bacteria-fingerprinting-technology-helps-doctors-diagnose-infection-accurately/)   Text: The idea is simple: when a patient has a bacterial infection, doctors should find out what kind of bacteria it is so they can give the most effective treatment. But growing bacteria in a lab to identify it takes hours to days. That means doctors have

ID Genomics and the University of Washington have long collaborated on developing cutting-edge technology that improves prescriptions of antibiotics for infectious diseases. To find out more about this collaboration, please read the UW Daily’s account of our technology here: http://www.dailyuw.com/science/article_7fc31298-289c-11e7-844c-c7e2e6368eaa.html

Many thanks to the Seattle Times for its coverage of ID Genomics’ technology. Please read the full text here:   Seattle health startup speeds up lab tests to improve use of antibiotics http://www.seattletimes.com/business/technology/seattle-health-startup-speeds-up-lab-tests-to-improve-use-of-antibiotics/